Navigation Links
The ideal composition of intravenous lipid emulsion

The body responds to a diverse range of insults, such as surgery, infection and injury by the activation of a wide range of cell types of the immune system, creating a number of potent cellular actions and mediators.// The inflammatory response, although essential for fighting infection, may damage the host. Its strength depends on pro- and anti-inflammatory mediators, cytokines and lipid mediators being the key mediators.

Recently, Robert Grimble, from the Institute of Human Nutrition, School of Medicine, University of Southampton, UK has reviewed the fatty acid profile of modern lipid emulsions, and the scientific considerations for creating the ideal composition.

In his report published in volume 1 of Clinical Nutrition Supplements, he states that in some types of patients, the lack of a correctly functioning gut precludes complete oral or enteral nutrient provision. As a consequence, the intravenous route assumes a greater importance for the provision of energy substrates, amino acids and micronutrients. Reliance on glucose as the main provider of energy to patients requiring intravenous nutrition led to metabolic complications. These include insulin insensitivity and metabolic acidosis due to the need to dispose of a large amount of metabolic breakdown products in the form of carbon dioxide.

Intravenous nutrition has been a life-saving technique in the treatment of severely ill patients, particularly in those where normal gut function is absent. However, the inability to provide sufficient energy to patients, in the form of glucose, led to the development of intravenous lipid emulsions.

These products were a major breakthrough in clinical nutrition particularly as insulin insensitivity is a major feature in the metabolism of severely ill patients. Previous studies have indicated that the use of lipid emulsions in clinical nutrition is not without limitations, but the inclusion of ù-3 fatty acids and fats rich in MUFAs a nd anti-oxidants in intravenous nutrition may successfully modulate inflammation and immunosuppression.

The creation of soybean oil-based lipid emulsions, for use in parenteral nutrition, was an important landmark in the science of nutritional treatment of surgical patients and individuals requiring critical care.

The primary importance of this development was that the energy requirements of the patient could be met without the metabolic burden imposed by high-level glucose infusion in situations of respiratory distress and insulin insensitivity. In soybean oil-based emulsions the ratio of ù-6 to ù-3 fatty acids is approximately 7:1. These classes of fatty acids compete for inclusion in cell membranes and result in the production of lipid mediators of differing potency.

The authors concludes on the note that recent studies suggest that increasing the ratio of ù-3 to ù-6 fatty acids and raising the monounsaturated fatty acid (MUFA) content of intravenous lipid emulsion is beneficial. MUFAs exert a neutral effect on metabolism. Thus ideal lipid solutions can be designed by adjustment of the ratio of ù-3, ù-6 and MUFAs
'"/>




Related medicine news :

1. The Link Between Oxidized Phospholipids And Coronary Artery Disease
2. Patients with HIV-1 can predict plasma lipids level based on race
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Thomas ... perseverance and disciplined exercise regime, the author was able to successfully recover. In “ ... all relevant information for various sources on the principals of massage, anatomy , ...
(Date:2/22/2017)... East Setauket, New York (PRWEB) , ... February ... ... the main floor entrance and lobby of a new healthcare contact center in ... gleaming results. , One of the nation’s largest healthcare systems recently invested $51 ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based ... velvet, announced its products are coming soon to Amazon.com, the world’s largest online retailer. ... as a means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which ...
(Date:2/22/2017)... ... 22, 2017 , ... The Waismann Method® is providing a faster, ... recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can be treated ... free from the shame, stigma, and harmful labeling believed to prevent many ...
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... February 23, 2017 ML Capital Group, Inc. ... Colorado Highlife Tours , a Colorado ... partnership with Puration, Inc. (USOTC: PURA) to enter Colorado,s ... product. The Colorado Highlife Tours acquisition announced today is intended to ... ...
(Date:2/23/2017)... 23, 2017 MabVax Therapeutics Holdings, ... development company, announces that it has received notice ... authorizing the initiation a Phase I clinical trial ... cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s ... to initiate the phase I clinical trial in ...
(Date:2/23/2017)... Wash. and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) today announced its year ... In January 2017, OncoGenex, and Achieve Life ... that they have entered into a definitive merger agreement ... transaction. Upon completion of the proposed merger, Achieve,s stockholders ...
Breaking Medicine Technology: